Amylyx Pharmaceuticals (AMLX) Net Margin Growth (1y) (2022 - 2024)
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) Net Margin Growth (1y) (2022 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 802.00 |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | -16,220.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -185.00 |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | -763.00 |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 529.00 |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 4,168.00 |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 2,208.00 |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -2,043.00 |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | -753,036.00 |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -401,516.00 |
| Sep 30, 2024 | -1.75 Mn |
| Jun 30, 2024 | -712,902.00 |
| Mar 31, 2024 | -13,622.00 |
| Dec 31, 2023 | 20,430.00 |
| Sep 30, 2023 | 1.56 Mn |
| Sep 30, 2022 | -746,145.00 |